Branding In-Vitro Protein 
XTalks
JULY 28, 2020
These data illustrate that while many excipient molecules are in fact inert, a good number may have previously unappreciated effects on human proteins known to play an important role in health and disease,” Shoichet said. But just how inert are these excipients?
Druggist
FEBRUARY 17, 2021
Most pharmacies sell hydrocortisone cream as ‘own’ label product or branded products, foe example HC45 Hydrocortisone cream. For many customers, ointment or cream for insect bites is the first line of rescue in stings management. I will also discuss alternative options for insect bites, mainly the use of antihistamines.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
The Pharma Data
JANUARY 31, 2021
Ion channels represent a large but under-exploited class of drug targets beyond G protein-coupled proteins (GPCRs). Ion channels are a class of integral membrane proteins that regulate the flow of ions across the cell membrane as a means of conducting signals between cells and their environment.
The Pharma Data
APRIL 29, 2022
About Evrysdi® (risdiplam) Evrysdi is a survival motor neuron 2 (SMN2) splicing modifier designed to treat SMA caused by mutations in chromosome 5q that lead to SMN protein deficiency. Evrysdi is designed to treat SMA by increasing and sustaining the production of the SMN protein in the central nervous system (CNS) and peripheral tissues.
The Pharma Data
MAY 31, 2022
About Evrysdi® (risdiplam) Evrysdi is a survival motor neuron 2 (SMN2) splicing modifier designed to treat SMA caused by mutations in chromosome 5q that lead to SMN protein deficiency. Evrysdi is now approved in the US to treat SMA in children and adults of all ages. Jude Children’s Research Hospital.
pharmaphorum
NOVEMBER 9, 2022
Meanwhile, NRG’s in vitro studies have shown its INDs to protect mitochondria and increase the viability of human cells, potentially able to halt or significantly slow progression of diseases such as Parkinson’s and ALS. In ALS , the protein TDP-43 triggers neuroinflammation via activation of the innate immune sensor STING.
The Pharma Data
MAY 27, 2022
This dual targeting activates and redirects a patient’s existing T-cells to engage and eliminate target B-cells by releasing cytotoxic proteins into the B-cells. The pivotal phase II NP30179 expansion study included patients with heavily pre-treated and highly refractory DLBCL, with 58.3% After a median follow-up of 12.6 months, 39.4%
Expert insights. Personalized for you.
103 
Let's personalize your content